ATE247461T1 - Formulierung zur intranasalen verabreichung - Google Patents

Formulierung zur intranasalen verabreichung

Info

Publication number
ATE247461T1
ATE247461T1 AT96941475T AT96941475T ATE247461T1 AT E247461 T1 ATE247461 T1 AT E247461T1 AT 96941475 T AT96941475 T AT 96941475T AT 96941475 T AT96941475 T AT 96941475T AT E247461 T1 ATE247461 T1 AT E247461T1
Authority
AT
Austria
Prior art keywords
analgesic
formulation
tramadol
intranasal administration
intranasal
Prior art date
Application number
AT96941475T
Other languages
English (en)
Inventor
Mark Alfonso
Paul Goldenheim
Richard Sackler
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE247461T1 publication Critical patent/ATE247461T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96941475T 1995-11-14 1996-11-14 Formulierung zur intranasalen verabreichung ATE247461T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/557,279 US6017963A (en) 1995-11-14 1995-11-14 Formulation for intranasal administration
PCT/US1996/018904 WO1997017948A1 (en) 1995-11-14 1996-11-14 Formulation for respiratory tract administration

Publications (1)

Publication Number Publication Date
ATE247461T1 true ATE247461T1 (de) 2003-09-15

Family

ID=24224765

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96941475T ATE247461T1 (de) 1995-11-14 1996-11-14 Formulierung zur intranasalen verabreichung

Country Status (8)

Country Link
US (3) US6017963A (de)
EP (1) EP0877609B1 (de)
JP (1) JP3152437B2 (de)
AT (1) ATE247461T1 (de)
AU (1) AU714303B2 (de)
CA (1) CA2234847C (de)
DE (1) DE69629591T2 (de)
WO (1) WO1997017948A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
ES2207867T3 (es) * 1998-12-11 2004-06-01 Pharmachemie B.V. Preparacion farmaceutica para inhalacion de un opioide.
WO2003090599A2 (en) * 2002-04-25 2003-11-06 Brainsgate Ltd. Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
SI1307194T2 (sl) * 2000-07-31 2011-07-29 Nycomed Danmark Aps Sestavek fentanila za nazalno dejanje
EP1315533A4 (de) * 2000-08-15 2007-06-27 Univ Kentucky Res Found Programmierbare mehrdosenvorrichtung für intranasale medikamentenverabreichung
DE10049483A1 (de) * 2000-09-29 2002-05-02 Gruenenthal Gmbh Substituierte 1-Aminobutan-3-ol-Derivate
JP2004509920A (ja) * 2000-09-29 2004-04-02 ボード　オブ　トラスティーズ　オペレーティング　ミシガン　ステート　ユニヴァーシティ カテコールアミン医薬組成物および方法
US20030053956A1 (en) * 2001-01-24 2003-03-20 Thomas Hofmann Alkylaryl polyether alcohol polymers for treatment and prophylaxis of snoring, sleep apnea, sudden infant death syndrome and for improvement of nasal breathing
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
CA2758923A1 (en) 2001-03-16 2002-09-26 Dmi Biosciences, Inc. Use of tramadol to delay ejaculation
WO2002094231A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of analgesics through an inhalation route
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
HUP0401022A3 (en) * 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
US6780891B2 (en) 2001-11-30 2004-08-24 Sepracor Inc. Tramadol analogs and uses thereof
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
ES2323169T3 (es) * 2002-08-06 2009-07-08 Glaxo Group Limited Dispensador.
AU2003269989B8 (en) * 2002-08-21 2009-11-12 Norton Healthcare Ltd. Inhalation composition
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
DE10248601B4 (de) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
AU2004322756B2 (en) 2004-08-12 2011-04-14 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
US20060045849A1 (en) * 2004-08-24 2006-03-02 Farhan Taghizadeh Method of customizing the fragrance of nasal medications
TWI436991B (zh) * 2004-11-22 2014-05-11 歐 賽提克股份有限公司 用於純化反-（-）-△９-四氫大麻酚與反-（＋）-△９-四氫大麻酚之方法
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
EP2522365B1 (de) 2004-11-24 2016-10-26 Meda Pharmaceuticals Inc. Zusammensetzungen aus Azelastin und Verwendungsverfahren dafür
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
JP2009504767A (ja) * 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ ビタミンｂ１２鼻用スプレーおよび使用方法
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
CN101325944B (zh) * 2005-10-11 2013-01-16 耶路撒冷希伯来大学伊萨姆研究开发公司 用于鼻部给药的组合物
EP1980271A4 (de) * 2006-01-27 2012-04-25 Asahi Kasei Pharma Corp Medizin zur transnasalen verabreichung
US20080319083A1 (en) * 2006-01-27 2008-12-25 Asahi Kasei Pharma Corporation Medicine for transnasal administration
US20080075771A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
NZ579170A (en) 2007-02-12 2012-05-25 Dmi Biosciences Inc Reducing side effects of tramadol
BRPI0807282A2 (pt) 2007-02-12 2014-04-29 Dmi Biosciences Inc Tratamento de ejaculação precoce e disfunção erétil co-mórbidas
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
EP2167069B1 (de) 2007-05-23 2011-10-26 Amcol International Corporation Mit cholesterin interagierende phyllosilikate und verfahren zur reduktion von hypercholesterinämie bei einem säuger
AU2009219204B2 (en) 2008-02-27 2013-01-17 Amcol International Corporation Methods of treating cardiovascular disorders associated with atherosclerosis
US20140088199A1 (en) * 2011-04-05 2014-03-27 Optosolve Llp Ophthalmic treatments
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
EP2668945A1 (de) * 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
CN104208044A (zh) * 2013-05-29 2014-12-17 天津金耀集团有限公司 盐酸曲马多吸入制剂
ES2604816B1 (es) 2015-09-09 2018-01-29 Farmalider, S.A. Composición farmacéutica de tramadol para uso oftálmico
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
JP7334145B2 (ja) * 2017-08-20 2023-08-28 ネイサス ファーマ リミテッド 鼻腔内送達用乾燥粉末組成物
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4440777A (en) * 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4624965A (en) * 1984-11-15 1986-11-25 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
EP0189861A3 (de) * 1985-01-26 1988-02-17 Showa Denko Kabushiki Kaisha Transdermaler Absorptionsbeschleuniger für ionische wasserlösliche Arzneistoffe
US4729997A (en) * 1985-10-15 1988-03-08 Nastech Pharmaceutical Co., Inc. Novel method of administering meclizine type pharmaceutical agents and novel dosage forms containing same
US5066648A (en) * 1985-11-29 1991-11-19 Merck & Co., Inc. Pyroglutamic acid esters used as dermal penetration enhancers for drugs
DE3602370A1 (de) * 1986-01-27 1987-08-06 Chrubasik Sigrun Verwendung von analgetica durch inhalation
US4778810A (en) * 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4973596A (en) * 1988-05-20 1990-11-27 Barr Laboratories, Inc. Method of administering a narcotic analgesic and dosage forms therefor
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
JP2875611B2 (ja) * 1990-08-29 1999-03-31 エーザイ株式会社 ケイ酸カルシウム含有外用剤
DE122004000032I2 (de) * 1991-09-06 2006-02-09 Mcneilab Inc Zusammensetzung die eine Tramadol-Verbindung und Acetaminophen enth{lt, und ihre Verwendung
ZA926732B (en) * 1991-09-06 1994-03-04 Mcneilab Inc Compositions comprising a tramadol material and any of codeine oxycodone or hydrocodone and their use
US5223541A (en) * 1991-09-13 1993-06-29 Mcneilab, Inc. Tramadol n-oxide material, enantiomers and compositions thereof, and their use
US5516803A (en) 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
WO1993015739A1 (fr) 1992-02-07 1993-08-19 Kaken Pharmaceutical Co., Ltd. Remede destine aux blessures ou aux hemorroides
DE4221256C2 (de) * 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
WO1994004139A1 (en) 1992-08-21 1994-03-03 Dana Farber Cancer Institute Treatment of human viral infections
WO1994010987A1 (en) * 1992-11-09 1994-05-26 Pharmetrix Corporation Combined analgesic delivery methods for pain management
JPH06199701A (ja) * 1992-12-29 1994-07-19 Lion Corp 外用消炎鎮痛剤
US5756483A (en) * 1993-03-26 1998-05-26 Merkus; Franciscus W. H. M. Pharmaceutical compositions for intranasal administration of apomorphine
EP0691848A1 (de) 1993-04-07 1996-01-17 Eisai Co., Ltd. Immunverstärkendes und infektionschützendes mittel, das zwei oder mehreren von bacillus, eiweiss und knoblauch enthält
US5451408A (en) * 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs

Also Published As

Publication number Publication date
US20020022663A1 (en) 2002-02-21
EP0877609B1 (de) 2003-08-20
DE69629591D1 (de) 2003-09-25
US6017963A (en) 2000-01-25
CA2234847C (en) 2002-06-25
US6642275B2 (en) 2003-11-04
AU714303B2 (en) 1999-12-23
CA2234847A1 (en) 1997-05-22
WO1997017948A1 (en) 1997-05-22
EP0877609A4 (de) 2000-06-07
AU1060497A (en) 1997-06-05
JP3152437B2 (ja) 2001-04-03
US20010049391A1 (en) 2001-12-06
EP0877609A1 (de) 1998-11-18
DE69629591T2 (de) 2004-07-01
JPH11500148A (ja) 1999-01-06

Similar Documents

Publication Publication Date Title
ATE247461T1 (de) Formulierung zur intranasalen verabreichung
EP0871488A4 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten
GB2367005A (en) Pharmaceutical formulations and methods comprising intranasal morphine
FI971404L (fi) Lääke nivelraumaan sisältäen IL-6-antagonistin aktiivisena aineena
SE9503924D0 (sv) Novel opioid peptides
ATE361077T1 (de) Indanylderivate zur behandlung von atemwegserkrankungen
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
DK0606366T3 (da) Substituerede phenseriner og phenylcarbamater af (-)-eserolin, (-)-N1-noreserolin og (-)-N1-benzylnoreserolin som specifikke inhibitorer af acetylcholinesterase
NO963850D0 (no) Heterosykliske forbindelser, deres fremstilling og anvendelse
DK1003494T3 (da) (d)-metadon, et ikke-opioidt analgetikum
DK1039900T3 (da) Farmaceutisk præparat indeholdende sibutramin og orlistat
BR9607541A (pt) Tratamento de doenças que tem por causa o fator de crescimento da citoquina
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
HUP9700661A2 (hu) Alfa1-adrenoreceptor antagonisták felhasználása rák megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására
TNSN99158A1 (ar) طريقة لمنع الاصابة بالربو
SE9502877D0 (sv) Novel opioid peptides
SE9802555D0 (sv) New pharmaceutical preparation and method
JO2127B1 (en) How to prevent asthma

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0877609

Country of ref document: EP